4.7 Review

Antidiabetic Drugs in the Treatment of Alzheimer's Disease

期刊

出版社

MDPI
DOI: 10.3390/ijms23094641

关键词

amyloid beta; Alzheimer type 3 diabetes mellitus; intranasal insulin; metformin; type 2 diabetes mellitus; incretins; PPAR gamma agonists; thiazolidinediones

向作者/读者索取更多资源

The public health burden of type 2 diabetes mellitus and Alzheimer's disease is increasing, especially in older adults. Recent studies have found that certain antidiabetic medications can improve cognition and memory in patients with Alzheimer's disease. This review examines the latest evidence for the potential use of antidiabetic medications in treating Alzheimer's disease.
The public health burden of type 2 diabetes mellitus and Alzheimer's disease is steadily increasing worldwide, especially in the population of older adults. Epidemiological and clinical studies suggest a possible shared pathophysiology between the two diseases and an increased risk of AD in patients with type 2 diabetes mellitus. Therefore, in recent years, there has been a substantial interest in identifying the mechanisms of action of antidiabetic drugs and their potential use in Alzheimer's disease. Human studies in patients with mild cognitive impairment and Alzheimer's disease have shown that administration of some antidiabetic medications, such as intranasal insulin, metformin, incretins, and thiazolidinediones, can improve cognition and memory. This review aims to examine the latest evidence on antidiabetic medications as a potential candidate for the treatment of Alzheimer's disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据